Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ArriVent BioPharma, Inc.
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
August 12, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 20, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
May 7, 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
April 30, 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
April 28, 2026